Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Christie’s International Real Estate Establishes Cryptocurrency Division to Advance Luxury Property Transactions with Digital Assets

Christie’s International Real Estate Establishes Cryptocurrency Division to Advance Luxury Property Transactions with Digital Assets

ChaincatcherChaincatcher2025/07/25 00:11
Show original

ChainCatcher reports that Christie’s International Real Estate has established a new division focused on property transactions conducted with cryptocurrency. This division aims to promote the purchase of luxury real estate using crypto, and is currently accepting pure cryptocurrency offers for luxury properties valued at $1 billion.

The Southern California branch president, Aaron Kirman, founded this division inspired by recent high-value crypto real estate sales. The division is staffed with a professional team of lawyers, analysts, and crypto experts, enabling cryptocurrency payments to be completed without intermediary banks. Kirman noted that he has overseen transactions where sellers were unaware of the buyers’ identities, but the seller’s agent’s lawyer would verify the legitimacy of the buyer’s funds.

After evaluating several high-value transactions using cryptocurrency over the past two years, Christie’s decided to establish this division. Most recently, at a client’s request, a $65 million real estate transaction in Beverly Hills, USA, was completed using cryptocurrency.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Bristol-Myers Squibb (BMY.US) rises in pre-market trading! Two experimental drugs report positive results in Phase 3 clinical trials, diversifying and accelerating the pipeline

Bristol Myers Squibb's two experimental drugs, used to treat a rare endocrine cancer and a deadly lung disease, have achieved success in Phase III clinical trials, injecting momentum into the pharmaceutical company’s new product pipeline.

智通财经•2026/10/12 12:36